nach oben

International Ophthalmology

Erschienen in:

01.12.2024 | Original Paper

Changes in ocular blood flow in patients with neovascular age-related macular degeneration after intravitreal injection of ranibizumab biosimilar and brolucizumab

verfasst von: Hiroki Takizawa, Masayuki Yasuda, Keisuke Hoshi, Tatsu Okabe, Hiroshi Kunikata, Toru Nakazawa

Erschienen in: International Ophthalmology | Ausgabe 1/2024

Einloggen, um Zugang zu erhalten

Abstract

Purpose

To assess ocular blood flow (OBF) changes in patients with neovascular age-related macular degeneration (nAMD) treated with intravitreal injections of ranibizumab biosimilar (IVRbs) or brolucizumab (IVBr).

Methods

This retrospective longitudinal study included 43 eyes of 43 patients (74.5 ± 9.8 years old, male to female ratio 31:12) with nAMD treated with IVBr (29 eyes) or IVRbs (14 eyes). OBF in the optic nerve head (ONH) and choroid (Ch) was measured with laser speckle flowgraphy (Softcare Co., Ltd., Fukutsu, Japan) before and one month after treatment. Changes in mean blur rate (MBR) before and after each treatment were tested using Wilcoxon’s signed-rank tests and mixed-effect models for repeated measures.

Results

In the IVBr group, MBR was significantly reduced in both the ONH and Ch (p < 0.01). In contrast, the IVRbs group showed no significant change in MBR in either the ONH or Ch (p = 0.56, p = 1). The linear mixed effect model showed a significant interaction between time and anti-VEGF drugs for MBR in both the ONH and Ch (ONH: p = 0.04; Ch: p = 0.002). A post hoc pairwise comparison of estimated marginal means showed that MBR decreased significantly only after IVBr (p < 0.001).

Conclusion

Our findings suggest that the short-term impact on OBF varies depending on the drug used for nAMD.

Nur mit Berechtigung zugänglich

Wong WL, Su X, Li X, Cheung CM, Klein R, Cheng CY, Wong TY (2014) Global prevalence of age-related macular degeneration and disease burden projection for 2020 and 2040: a systematic review and meta-analysis. Lancet Glob Health 2:e106–e116. https://doi.org/10.1016/S2214-109X(13)70145-1CrossRefPubMed

Deng Y, Qiao L, Du M, Qu C, Wan L, Li J, Huang L (2022) Age-related macular degeneration: epidemiology, genetics, pathophysiology, diagnosis, and targeted therapy. Genes Dis 9:62–79. https://doi.org/10.1016/j.gendis.2021.02.009CrossRefPubMed

Kwak N, Okamoto N, Wood JM, Campochiaro PA (2000) VEGF Is Major Stimulator in Model of Choroidal Neovascularization. Invest Ophthalmol Vis Sci 41:3158–3164PubMed

Hood JD, Meininger CJ, Ziche M, Granger HJ (1998) VEGF upregulates ecNOS message, protein, and NO production in human endothelial cells. Am J Physiol Heart Circ Physiol 274:H1054–H1058. https://doi.org/10.1152/ajpheart.1998.274.3.H1054CrossRef

Maguire MG, Martin DF, Ying GS, Jaffe GJ, Daniel E, Grunwald JE, Toth CA, Ferris FL 3rd, Fine SL (2016) Five-year outcomes with anti-vascular endothelial growth factor treatment of neovascular age-related macular degeneration: the comparison of age-related macular degeneration treatments trials. Ophthalmology 123:1751–1761. https://doi.org/10.1016/j.ophtha.2016.03.045CrossRefPubMed

Hosseini H, Rabina G, Pettenkofer M, Au A, Chehaibou I, Heilweil G, Weiner AJ, Ip M, Loewenstein A, Schwartz SD (2021) Clinical characteristics and visual outcomes of non-resolving subretinal fluid in neovascular AMD despite continuous monthly anti-VEGF injections: a long-term follow-up. Graefes Arch Clin Exp Ophthalmol 259:1153–1160. https://doi.org/10.1007/s00417-020-05024-9/PublishedCrossRefPubMed

Lee A, Garg PG, Lyon AT, Mirza R, Gill MK (2020) Long-term outcomes of treat and extend regimen of anti-vascular endothelial growth factor in neovascular age-related macular degeneration. J Ophthalmic Vis Res 15:331–340. https://doi.org/10.18502/jovr.v15i3.7452CrossRefPubMedPubMedCentral

Papapetropoulos A, García-Cardeña G, Madri JA, Sessa WC (1997) Nitric oxide mediates the actions of VEGF nitric oxide production contributes to the angiogenic properties of vascular endothelial growth factor in human endothelial cells. J Clin Invest 100:3131–3139. https://doi.org/10.1172/JCI119868CrossRefPubMedPubMedCentral

Resch MD, Balogh A, Kurth T, Nagy ZZ, DeBuc DC, Papp A (2022) Atrophy of retinal vessels in neovascular age-related macular degeneration following long-term treatment with 20 intravitreal anti-VEGF injections. BMC Ophthalmol 22:469. https://doi.org/10.1186/s12886-022-02700-8CrossRefPubMedPubMedCentral

10.

Mursch-Edlmayr AS, Luft N, Podkowinski D, Ring M, Schmetterer L, Bolz M (2020) Effects of three intravitreal injections of aflibercept on the ocular circulation in eyes with age-related maculopathy. Br J Ophthalmol 104:53–57. https://doi.org/10.1136/bjophthalmol-2019-313919CrossRefPubMed

11.

Hatamnejad A, Dadak R, Orr S, Wykoff C, Choudhry N (2023) Systematic review of efficacy and meta-analysis of safety of ranibizumab biosimilars relative to reference ranibizumab anti-VEGF therapy for nAMD treatment. BMJ Open Ophthalmol 8:e001205. https://doi.org/10.1136/bmjophth-2022-001205CrossRefPubMedPubMedCentral

12.

Mottet B, Aptel F, Geiser MH, Hera R, Zhou T, Almanjoumi A, Vinh V, Chiquet C (2018) Choroidal blood flow after the first intravitreal ranibizumab injection in neovascular age-related macular degeneration patients. Acta Ophthalmol 96:e783–e788. https://doi.org/10.1111/aos.13763CrossRefPubMed

13.

Nguyen QD, Das A, Do DV, Dugel PU, Gomes A, Holz FG, Koh A, Pan CK, Sepah YJ, Patel N, MacLeod H, Maurer P (2020) Brolucizumab: Evolution through preclinical and clinical studies and the implications for the management of neovascular age-related macular degeneration. Ophthalmology 127:963–976. https://doi.org/10.1016/j.ophtha.2019.12.031CrossRefPubMed

14.

Dugel PU, Singh RP, Koh A, Ogura Y, Weissgerber G, Gedif K, Jaffe GJ, Tadayoni R, Schmidt-Erfurth U, Holz FG (2021) HAWK and HARRIER: 96 week outcomes from the phase 3 trials of brolucizumab for neovascular age-related macular degeneration. Ophthalmology 129:593–596

15.

Holz FG, Dugel PU, Weissgerber G, Hamilton R, Silva R, Bandello F, Larsen M, Weichselberger A, Wenzel A, Schmidt A, Escher D, Sararols L, Souied E (2016) Single-Chain antibody fragment VEGF Inhibitor RTH258 for neovascular age-related macular degeneration: a randomized controlled study. Ophthalmology 123:1080–1089CrossRefPubMed

16.

Pignatelli F, Niro A, Passidomo F, Addabbo G (2021) Molecular structure, pharmacokinetics and clinical evidence of brolucizumab: a narrative review. Ann Eye Sci 6:37. https://doi.org/10.21037/aes-21-41CrossRef

17.

Bird A, Bressler N, Bressler S, Chisholm IH, Coscas G, Davis MD, de Jong PT, Klaver CC, Klein BE, Klein R et al (1995) An international classification and grading system for age-related maculopathy and age-related macular degeneration. The International ARM epidemiological study group. Surv Ophthalmol 39:367–374. https://doi.org/10.1016/s0039-6257(05)80092-xCrossRefPubMed

18.

Guymer R, Wu Z (2020) Age-related macular degeneration (AMD): more than meets the eye. The role of multimodal imaging in today’s management of AMD-A review. Clin Exp Ophthalmol 48:983–995. https://doi.org/10.1111/ceo.13837CrossRefPubMed

19.

Kiyota N, Shiga Y, Ichinohasama K, Yasuda M, Aizawa N, Omodaka K, Honda N, Kunikata H, Nakazawa T (2018) The impact of intraocular pressure elevation on optic nerve head and choroidal blood flow. Invest Ophthalmol Vis Sci 59:3488–3496. https://doi.org/10.1167/iovs.18-23872CrossRefPubMed

20.

Sugiyama T, Araie M, Riva CE, Schmetterer L, Orgul S (2010) Use of laser speckle flowgraphy in ocular blood flow research. Acta Ophthalmol 88:723–729. https://doi.org/10.1111/j.1755-3768.2009.01586.xCrossRefPubMed

21.

Mallinckrodt CH, Clark WS, David SR (2001) Accounting for dropout bias using mixed-effects models. J Biopharm Stat 11:9–21. https://doi.org/10.1081/BIP-100104194CrossRefPubMed

22.

Lenth RV (2023) emmeans: estimated marginal means, aka least-squares means. The comprehensive R archive network. https://CRAN.R-project.org/package=emmeans. Accessed 11 January 2024

23.

Posit team (2023) RStudio: integrated development environment for R. Posit. https://posit.co/downloads/. Accessed 11 January 2024

24.

Asano T, Kunikata H, Yasuda M, Nishiguchi KM, Abe T, Nakazawa T (2021) Ocular microcirculation changes, measured with laser speckle flowgraphy and optical coherence tomography angiography, in branch retinal vein occlusion with macular edema treated by ranibizumab. Int Ophthalmol 41:151–162. https://doi.org/10.1007/s10792-020-01562-7CrossRefPubMed

25.

Shiga Y, Asano T, Kunikata H, Nitta F, Sato H, Nakazawa T, Shimura M (2014) Relative flow volume, a novel blood flow index in the human retina derived from laser speckle flowgraphy. Invest Ophthalmol Vis Sci 55:3899–3904. https://doi.org/10.1167/iovs.14-14116CrossRefPubMed

26.

Calzetti G, Mora P, Borrelli E, Sacconi R, Ricciotti G, Carta A, Gandolfi S, Querques G (2021) Short-term changes in retinal and choroidal relative flow volume after anti-VEGF treatment for neovascular age-related macular degeneration. Sci Rep 11:23723. https://doi.org/10.1038/s41598-021-03179-xCrossRefPubMedPubMedCentral

27.

Hoshi K, Kunikata H, Aizawa N, Yasuda M, Okabe T, Takizawa H, Abe T, Nakazawa T (2023) Baseline characteristics associated with the incidence of intraocular inflammation after the intravitreous injection of brolucizumab. Int Ophthalmol 43:4701–4709. https://doi.org/10.1007/s10792-023-02870-4CrossRefPubMed

28.

Kato N, Haruta M, Furushima K, Arai R, Matsuo Y, Yoshida S (2023) Decrease in ocular blood flow 30 minutes after intravitreal injections of brolucizumab and aflibercept for neovascular age-related macular degeneration. Clin Ophthalmol 17:1187–1192. https://doi.org/10.2147/OPTH.S407249CrossRefPubMedPubMedCentral

Titel: Changes in ocular blood flow in patients with neovascular age-related macular degeneration after intravitreal injection of ranibizumab biosimilar and brolucizumab
verfasst von: Hiroki Takizawa
Masayuki Yasuda
Keisuke Hoshi
Tatsu Okabe
Hiroshi Kunikata
Toru Nakazawa
Publikationsdatum: 01.12.2024
Verlag: Springer Netherlands
Erschienen in: International Ophthalmology / Ausgabe 1/2024
Print ISSN: 0165-5701
Elektronische ISSN: 1573-2630
DOI: https://doi.org/10.1007/s10792-024-03107-8

Neu im Fachgebiet Augenheilkunde

Metastase in der periokulären Region

Metastasen Leitthema

Orbitale und periokuläre metastatische Tumoren galten früher als sehr selten. Aber mit der ständigen Aktualisierung von Medikamenten und Nachweismethoden für die Krebsbehandlung werden neue Chemotherapien und Strahlenbehandlungen eingesetzt. Die …

Staging und Systemtherapie bei okulären und periokulären Metastasen

Metastasen Leitthema

Metastasen bösartiger Erkrankungen sind die häufigsten Tumoren, die im Auge diagnostiziert werden. Sie treten bei ungefähr 5–10 % der Patienten mit soliden Tumoren im Verlauf der Erkrankung auf. Besonders häufig sind diese beim Mammakarzinom und …

Wundheilung nach Trabekulektomie

Trabekulektomie CME-Artikel

Die überschießende Wundheilung in der filtrierenden Glaukomchirurgie ist ein zentraler Faktor für ein operatives Versagen. Nach der Einführung der Trabekulektomie in den 1960er-Jahren wurden viele Faktoren erkannt, die mit einer vermehrten …

„standard operating procedures“ (SOP) – Vorschlag zum therapeutischen Management bei periokulären sowie intraokulären Metastasen

Metastasen Leitthema

Peri- sowie intraokuläre Metastasen sind insgesamt gesehen selten und meist Zeichen einer fortgeschrittenen primären Tumorerkrankung. Die Therapie ist daher zumeist palliativ und selten kurativ. Zudem ist die Therapiefindung sehr individuell. Die …

Update Augenheilkunde

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Die Highlights vom Kongress des American College of Cardiology 2024

Springer Medizin

Changes in ocular blood flow in patients with neovascular age-related macular degeneration after intravitreal injection of ranibizumab biosimilar and brolucizumab

Abstract

Purpose

Methods

Results

Conclusion

Neu im Fachgebiet Augenheilkunde

Metastase in der periokulären Region

Staging und Systemtherapie bei okulären und periokulären Metastasen

Wundheilung nach Trabekulektomie

„standard operating procedures“ (SOP) – Vorschlag zum therapeutischen Management bei periokulären sowie intraokulären Metastasen

Update Augenheilkunde

Die Highlights vom Kongress des American College of Cardiology 2024

Springer Medizin

Abstract

Purpose

Methods

Results

Conclusion

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 1/2024

Corneal aberrations in primary congenital glaucoma and its visual correlation

Evaluation of dry eye disease and corneal epithelial mapping in patients with lower eyelid ectropion

Comparing the diagnostic accuracy of MR dacryocystography (MRD) and dacryoscintigraphy (DSG) in NLDO-related acquired epiphora

Refractive outcomes of small lenticule extraction (SMILE) Pro® with a 2 MHz femtosecond laser

Association between metformin use and the risk of developing open-angle glaucoma among patients with diabetes: a retrospective cohort study and meta-analysis

Congenital ptosis with aponeurotic maldevelopment: clinical and surgical perspectives

Neu im Fachgebiet Augenheilkunde

Metastase in der periokulären Region

Staging und Systemtherapie bei okulären und periokulären Metastasen

Wundheilung nach Trabekulektomie

„standard operating procedures“ (SOP) – Vorschlag zum therapeutischen Management bei periokulären sowie intraokulären Metastasen

Update Augenheilkunde